Synopsis
Marketing authorisation holders are advised to submit any type IB variations or groupings of type IBs and type IAs by 30 November 2026 for a start of procedure in 2026. This may impact our usual timelines for validation and responses to queries for all type I variations (IA and IB).
Automatically extracted from the original page. This is a short summary, not the full story, and may omit important detail.
Read the full story at European Medicines Agency: news ↗